Waters Corporation (0LTI.L)
USD 325.39
(-5.2%)
USD 325.39
(-5.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.96 Billion USD | 67.45% |
| 2022 | 1.17 Billion USD | 15.62% |
| 2021 | 1.01 Billion USD | 10.09% |
| 2020 | 919.82 Million USD | -31.63% |
| 2019 | 1.34 Billion USD | -10.32% |
| 2018 | 1.5 Billion USD | -53.88% |
| 2017 | 3.25 Billion USD | 7.59% |
| 2016 | 3.02 Billion USD | 13.09% |
| 2015 | 2.67 Billion USD | 156.33% |
| 2014 | 1.04 Billion USD | 18.19% |
| 2013 | 882.55 Million USD | 26.67% |
| 2012 | 696.74 Million USD | 14.82% |
| 2011 | 606.84 Million USD | 32.63% |
| 2010 | 457.55 Million USD | 57.42% |
| 2009 | 290.66 Million USD | 170.14% |
| 2008 | 107.59 Million USD | -62.49% |
| 2007 | 286.84 Million USD | -26.32% |
| 2006 | 389.29 Million USD | 17.01% |
| 2005 | 332.69 Million USD | 503.69% |
| 2004 | -82.41 Million USD | 25.4% |
| 2003 | -110.47 Million USD | 57.62% |
| 2002 | -260.64 Million USD | -15.51% |
| 2001 | -225.65 Million USD | -219.49% |
| 2000 | -70.63 Million USD | -177.19% |
| 1999 | 91.5 Million USD | -57.85% |
| 1998 | 217.1 Million USD | -29.88% |
| 1997 | 309.6 Million USD | 46.31% |
| 1996 | 211.6 Million USD | 34.61% |
| 1995 | 157.2 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -306.11 Million USD | -10.67% |
| 2024 Q2 | 1.76 Billion USD | -2.16% |
| 2024 Q1 | 1.8 Billion USD | -12.01% |
| 2023 Q4 | 2.04 Billion USD | -9.24% |
| 2023 Q2 | 2.39 Billion USD | 121.43% |
| 2023 FY | 1.96 Billion USD | 67.45% |
| 2023 Q1 | 1.08 Billion USD | -7.68% |
| 2023 Q3 | 2.25 Billion USD | -5.75% |
| 2022 Q1 | 990.14 Million USD | -4.84% |
| 2022 FY | 1.17 Billion USD | 15.62% |
| 2022 Q4 | 1.17 Billion USD | -0.38% |
| 2022 Q3 | 1.17 Billion USD | 3.03% |
| 2022 Q2 | 1.14 Billion USD | 15.2% |
| 2021 FY | 1.01 Billion USD | 10.09% |
| 2021 Q1 | 1.14 Billion USD | 4.43% |
| 2021 Q4 | 1.04 Billion USD | -6.74% |
| 2021 Q2 | 1.17 Billion USD | 2.15% |
| 2021 Q3 | 1.11 Billion USD | -4.71% |
| 2020 Q3 | 1.37 Billion USD | -10.48% |
| 2020 Q4 | 1.09 Billion USD | -20.07% |
| 2020 FY | 919.82 Million USD | -31.63% |
| 2020 Q1 | 3.41 Billion USD | 14.11% |
| 2020 Q2 | 1.53 Billion USD | -55.09% |
| 2019 FY | 1.34 Billion USD | -10.32% |
| 2019 Q4 | 2.99 Billion USD | 31.97% |
| 2019 Q1 | 1.57 Billion USD | 5.29% |
| 2019 Q3 | 2.26 Billion USD | 35.34% |
| 2019 Q2 | 1.67 Billion USD | 6.09% |
| 2018 Q3 | 1.6 Billion USD | 3.4% |
| 2018 Q1 | 1.77 Billion USD | -45.31% |
| 2018 Q4 | 1.5 Billion USD | -6.65% |
| 2018 FY | 1.5 Billion USD | -53.88% |
| 2018 Q2 | 1.55 Billion USD | -12.64% |
| 2017 Q1 | 2.92 Billion USD | -3.26% |
| 2017 Q4 | 3.25 Billion USD | 5.4% |
| 2017 Q3 | 3.08 Billion USD | 1.78% |
| 2017 Q2 | 3.03 Billion USD | 3.67% |
| 2017 FY | 3.25 Billion USD | 7.59% |
| 2016 Q2 | 2.92 Billion USD | 1.02% |
| 2016 FY | 3.02 Billion USD | 13.09% |
| 2016 Q4 | 3.02 Billion USD | 0.5% |
| 2016 Q3 | 3 Billion USD | 2.85% |
| 2016 Q1 | 2.89 Billion USD | 8.3% |
| 2015 Q3 | 2.62 Billion USD | 1.79% |
| 2015 Q4 | 2.67 Billion USD | 1.83% |
| 2015 Q1 | 2.35 Billion USD | 125.73% |
| 2015 Q2 | 2.57 Billion USD | 9.55% |
| 2015 FY | 2.67 Billion USD | 156.33% |
| 2014 Q4 | 1.04 Billion USD | -2.79% |
| 2014 Q1 | 936.72 Million USD | 6.14% |
| 2014 Q2 | 964.71 Million USD | 2.99% |
| 2014 Q3 | 1.07 Billion USD | 11.23% |
| 2014 FY | 1.04 Billion USD | 18.19% |
| 2013 Q2 | 812.86 Million USD | 6.79% |
| 2013 FY | 882.55 Million USD | 26.67% |
| 2013 Q4 | 882.55 Million USD | 2.29% |
| 2013 Q3 | 862.76 Million USD | 6.14% |
| 2013 Q1 | 761.18 Million USD | 9.25% |
| 2012 Q1 | 596.47 Million USD | -1.71% |
| 2012 Q2 | 731.92 Million USD | 22.71% |
| 2012 Q3 | 791.41 Million USD | 8.13% |
| 2012 Q4 | 696.74 Million USD | -11.96% |
| 2012 FY | 696.74 Million USD | 14.82% |
| 2011 Q2 | 491.26 Million USD | -0.45% |
| 2011 FY | 606.84 Million USD | 32.63% |
| 2011 Q1 | 493.48 Million USD | 7.85% |
| 2011 Q3 | 547.65 Million USD | 11.48% |
| 2011 Q4 | 606.84 Million USD | 10.81% |
| 2010 Q1 | 415.37 Million USD | 42.91% |
| 2010 FY | 457.55 Million USD | 57.42% |
| 2010 Q4 | 457.55 Million USD | -13.58% |
| 2010 Q3 | 529.44 Million USD | 18.72% |
| 2010 Q2 | 445.97 Million USD | 7.37% |
| 2009 Q2 | 272.31 Million USD | 36.22% |
| 2009 FY | 290.66 Million USD | 170.14% |
| 2009 Q4 | 290.66 Million USD | 14.33% |
| 2009 Q3 | 254.23 Million USD | -6.64% |
| 2009 Q1 | 199.9 Million USD | 85.79% |
| 2008 Q2 | 153.33 Million USD | -32.96% |
| 2008 FY | 107.59 Million USD | -62.49% |
| 2008 Q4 | 107.59 Million USD | -20.23% |
| 2008 Q1 | 228.74 Million USD | -20.26% |
| 2008 Q3 | 134.88 Million USD | -12.03% |
| 2007 Q2 | 345.11 Million USD | -6.17% |
| 2007 Q4 | 286.84 Million USD | -10.15% |
| 2007 Q3 | 319.25 Million USD | -7.49% |
| 2007 Q1 | 367.81 Million USD | -5.52% |
| 2007 FY | 286.84 Million USD | -26.32% |
| 2006 Q1 | 356.95 Million USD | 7.29% |
| 2006 Q3 | 374.32 Million USD | 0.41% |
| 2006 Q4 | 389.29 Million USD | 4.0% |
| 2006 FY | 389.29 Million USD | 17.01% |
| 2006 Q2 | 372.78 Million USD | 4.44% |
| 2005 Q2 | 42.2 Million USD | 4419.86% |
| 2005 Q4 | 332.69 Million USD | 101.77% |
| 2005 FY | 332.69 Million USD | 503.69% |
| 2005 Q1 | -977 Thousand USD | 98.81% |
| 2005 Q3 | 164.88 Million USD | 290.68% |
| 2004 Q2 | -10.48 Million USD | 80.29% |
| 2004 Q3 | -78.47 Million USD | -648.58% |
| 2004 Q1 | -53.17 Million USD | 51.86% |
| 2004 FY | -82.41 Million USD | 25.4% |
| 2004 Q4 | -82.41 Million USD | -5.02% |
| 2003 Q3 | -83.67 Million USD | 49.95% |
| 2003 Q1 | -175.51 Million USD | 32.66% |
| 2003 FY | -110.47 Million USD | 57.62% |
| 2003 Q4 | -110.47 Million USD | -32.02% |
| 2003 Q2 | -167.2 Million USD | 4.73% |
| 2002 FY | -260.64 Million USD | -15.51% |
| 2002 Q4 | -260.64 Million USD | -11.08% |
| 2002 Q3 | -234.64 Million USD | 23.19% |
| 2002 Q2 | -305.49 Million USD | -22.62% |
| 2002 Q1 | -249.14 Million USD | -10.41% |
| 2001 Q4 | -225.65 Million USD | -38.35% |
| 2001 FY | -225.65 Million USD | -219.49% |
| 2001 Q2 | -132.33 Million USD | -52.26% |
| 2001 Q1 | -86.91 Million USD | -23.06% |
| 2001 Q3 | -163.1 Million USD | -23.25% |
| 2000 FY | -70.63 Million USD | -177.19% |
| 2000 Q1 | 55.02 Million USD | -39.86% |
| 2000 Q2 | 10.98 Million USD | -80.04% |
| 2000 Q3 | -5.77 Million USD | -152.6% |
| 2000 Q4 | -70.63 Million USD | -1122.82% |
| 1999 Q4 | 91.5 Million USD | -18.67% |
| 1999 FY | 91.5 Million USD | -57.85% |
| 1999 Q1 | 184.8 Million USD | -14.88% |
| 1999 Q2 | 148 Million USD | -19.91% |
| 1999 Q3 | 112.5 Million USD | -23.99% |
| 1998 Q1 | 299.3 Million USD | -3.33% |
| 1998 FY | 217.1 Million USD | -29.88% |
| 1998 Q2 | 285.1 Million USD | -4.74% |
| 1998 Q3 | 255.7 Million USD | -10.31% |
| 1998 Q4 | 217.1 Million USD | -15.1% |
| 1997 Q2 | 179.7 Million USD | -7.47% |
| 1997 Q3 | 334.6 Million USD | 86.2% |
| 1997 Q4 | 309.6 Million USD | -7.47% |
| 1997 FY | 309.6 Million USD | 46.31% |
| 1997 Q1 | 194.2 Million USD | -8.22% |
| 1996 FY | 211.6 Million USD | 34.61% |
| 1996 Q1 | 142.6 Million USD | -9.29% |
| 1996 Q2 | 236.8 Million USD | 66.06% |
| 1996 Q4 | 211.6 Million USD | -6.16% |
| 1996 Q3 | 225.5 Million USD | -4.77% |
| 1995 Q1 | 258.4 Million USD | 0.0% |
| 1995 Q4 | 157.2 Million USD | -34.69% |
| 1995 Q2 | 247 Million USD | -4.41% |
| 1995 FY | 157.2 Million USD | 0.0% |
| 1995 Q3 | 240.7 Million USD | -2.55% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 2004.243% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 6380.03% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -889.795% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -6048.462% |
| bluebird bio, Inc. | 108.57 Million USD | -1705.673% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 21843.977% |
| Imunon, Inc. | -4.69 Million USD | 41817.878% |
| Editas Medicine, Inc. | -87.11 Million USD | 2350.375% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 84.75% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 6.555% |
| Myriad Genetics, Inc. | 88.1 Million USD | -2125.241% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -1005.717% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 5947.338% |
| Verastem, Inc. | -37.27 Million USD | 5358.965% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 76.194% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 92.696% |
| Biogen Inc. | 6.28 Billion USD | 68.824% |
| Nektar Therapeutics | 210.24 Million USD | -832.476% |
| Perrigo Company plc | 3.32 Billion USD | 40.988% |
| Dynavax Technologies Corporation | 106.63 Million USD | -1738.455% |
| Illumina, Inc. | 1.21 Billion USD | -61.486% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -28034.552% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 1821.373% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -1251.317% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -27177.543% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -417.61% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 27711.789% |
| Evolus, Inc. | 63.7 Million USD | -2977.223% |
| Adicet Bio, Inc. | -142 Million USD | 1480.512% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 5426.695% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 7334.085% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -327.391% |
| FibroGen, Inc. | 56.76 Million USD | -3353.48% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -71.217% |
| OPKO Health, Inc. | 230.68 Million USD | -749.84% |
| Homology Medicines, Inc. | 18.43 Million USD | -10533.167% |
| Geron Corporation | 14.76 Million USD | -13181.194% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | -23.661% |
| Exelixis, Inc. | -73.05 Million USD | 2783.692% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 3713.309% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 1398.096% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 1859.786% |
| Zoetis Inc. | 4.76 Billion USD | 58.832% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 1081.097% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 19566.16% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 120.498% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 13553.452% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -85.952% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -102.445% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 1547.886% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | -41.97% |
| Blueprint Medicines Corporation | 702.83 Million USD | -178.932% |
| Insmed Incorporated | 721.62 Million USD | -171.672% |
| TG Therapeutics, Inc. | 17.86 Million USD | -10875.462% |
| Incyte Corporation | -3.17 Billion USD | 161.744% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -155.999% |